IN-DATE
SSG-5080-SIM1: TriSalus SureFire 5F Flexion Guiding Catheter 80cm, SIM 1
Sign in to add this product to your favorites!
| Price: | $46.50 EACH |
|---|---|
| Quantity: | |
| In Stock: | 2 eaches |
| Status: | expired |
| Express: | Need it tomorrow? Order in next 14 hours 41 minutes and choose overnight shipping at checkout for Monday delivery. If you require Saturday delivery, please call to determine if it is available in your area - 888-416-2409. |
AccessGUDID Info
- FDA Product Code: DQY
- FDA Product Code Name: Catheter, Percutaneous
- GMDN Term Code: 17846
- GMDN Term Name: Vascular guide-catheter, single-use
- GMDN Term Description: A flexible tube intended to be used for the percutaneous transluminal passage and placement of a diagnostic/interventional catheter, lead (e.g., pacing lead, balloon dilatation catheter), needle or guidewire through its lumen(s), within the vascular system. It may be rigid or flexible, non-steerable or steerable, single or multiple lumen(s), and the distal section can have a variety of preformed shapes (e.g., straight, hockey stick). It is not intended solely for infusion, is not intended to access superselective small vessels, and does not include a transseptal needle. It may include a disposable percutaneous introduction set or shaft visualization electrodes. This is a single-use device.
Manufacturer
TriSalus Life Sciences is transforming regional cancer treatment with innovative technologies designed to improve drug delivery to solid tumors. At the core of TriSalus’ platform is the TriNav™ Infusion System, a next-generation tool engineered for Pressure-Enabled Drug Delivery™ (PEDD™)—a proprietary method that enhances therapeutic uptake by overcoming high interstitial pressure in solid tumors.
The TriNav™ Infusion System enables precise intravascular administration of immunotherapeutics and chemotherapy agents directly to diseased tissue, making it especially effective for treating primary and metastatic liver tumors, pancreatic cancer, and other hard-to-treat abdominal cancers. With its smart design and compatibility with standard interventional radiology techniques, TriNav™ supports optimized delivery to the tumor microenvironment while reducing systemic exposure.
TriSalus’ integrated approach pairs PEDD™ technology with regional immunotherapy strategies, addressing immune suppression within the tumor microenvironment and unlocking new potential for checkpoint inhibitors and other immunotherapies. With a growing clinical pipeline and ongoing trials across leading cancer centers, TriSalus Life Sciences is committed to improving outcomes in patients with unresectable or treatment-resistant tumors.
